Brainstorm Cell Therapeutics announces results of Phase 2 study of NurOwnÂ® in Patients with Amyotrophic Lateral Sclerosis (ALS).
19 Jul 2016
Brainstorm develops adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. Results of a Phase 2 study announced on 18 July 2016 demonstrated that NurOwn was safe and well tolerated. It was also reported to achieve secondary efficacy endpoints indicating evidence of clinical benefit in a 24 week study. http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=174193#.V5tm0PkrJhE#ixzz4Fo8eXT2v